Pain Therapeutics (PTIE) Posts Quarterly Results
Pain Therapeutics (NASDAQ:PTIE) released its earnings data on Thursday. The company reported ($0.02) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by $0.01, American Banking and Market News reports. The company had revenue of $1.96 million for the quarter, compared to the consensus estimate of $2.00 million.
On the ratings front, analysts at Zacks upgraded shares of Pain Therapeutics from a “neutral” rating to an “outperform” rating in a research note to investors on Monday. They now have a $4.10 price target on the stock.
Shares of Pain Therapeutics (NASDAQ:PTIE) traded down 4.41% during mid-day trading on Thursday, hitting $3.661. The stock had a trading volume of 198,622 shares. Pain Therapeutics has a 52-week low of $2.15 and a 52-week high of $5.86. The stock’s 50-day moving average is $2.95 and its 200-day moving average is $2.79. The company’s market cap is $166.3 million.
Pain Therapeutics, Inc is a biopharmaceutical company that develops drugs. The Company has four drug candidates in clinical programs, including REMOXY, abuse-resistant hydromorphone, abuse-resistant hydrocodone and a radio-labeled monoclonal antibody to treat metastatic melanoma.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.